RecruitingNot ApplicableNCT06068075

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study

Sponsor

Dana-Farber Cancer Institute

Enrollment

340 participants

Start Date

May 8, 2018

Study Type

INTERVENTIONAL

Conditions

Ewing Sarcoma Peripheral Primitive Neuroectodermal Tumor Ewing Sarcoma of Bone Ewing Sarcoma of Soft Tissue Peripheral Primitive Neuroectodermal Tumor of Bone Peripheral Primitive Neuroectodermal Tumor of Soft Tissue

Summary

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

Eligibility

Min Age: 12 MonthsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study (called LEOPARD) tests whether liquid biopsy — a blood test that detects tiny fragments of cancer DNA — can predict outcomes and track treatment response in young patients with Ewing sarcoma or osteosarcoma (types of bone/soft tissue cancer). **You may be eligible if...** - You are between 12 months and 50 years old - You have a newly diagnosed Ewing sarcoma, peripheral PNET (a related tumor), or high-grade osteosarcoma that is localized or has spread to nearby areas only (not distant metastases for osteosarcoma) - Your diagnosis has been confirmed by a pathologist **You may NOT be eligible if...** - Your osteosarcoma is located in the pelvis (pelvic location is excluded) - You have distant metastases at diagnosis (for osteosarcoma) - You are younger than 12 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFoundationOne Liquid CDx

a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center

Locations(15)

Childrens Hospital Los Angeles

Los Angeles, California, United States

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Children's Hospital's and Clinics of Minnesota

Minneapolis, Minnesota, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Lifespan / Rhode Island Hospital

Providence, Rhode Island, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

UT Southwestern Medical Center

Dallas, Texas, United States

University of Utah Childrens Medical Center

Salt Lake City, Utah, United States

Seattle Children's Hospital

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06068075

Related Trials

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT064413315 locations

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

NCT069262833 locations

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

NCT067965432 locations

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

NCT072979793 locations

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT048973211 location